Elon Musk’s start-up Neuralink said on Thursday that it has received approval from the US Food and Drug Administration to begin human trials of its brain implant technology.

The company said the approval is for a small clinical trial of up to 10 people with severe neurological conditions, such as paralysis or blindness.

The trial will test the safety and effectiveness of Neuralink’s implant, which is designed to allow people to control computers and other devices with their thoughts.

“This is an important first step for Neuralink, and we are excited to begin testing our technology in people,” said Musk, Neuralink’s co-founder and CEO.

“We believe that our technology has the potential to revolutionize the way people with neurological conditions live and interact with the world.”

Neuralink’s implant is a small, coin-sized device that is surgically implanted into the brain. The device contains a network of electrodes that can be used to record and stimulate neural activity.

Musk’s company says that the implant can be used to restore lost function in people with neurological conditions, such as paralysis or blindness.

The FDA approval for Neuralink’s clinical trial is a significant milestone for the company. The approval process is rigorous, and it takes years for most medical devices to receive FDA approval. Neuralink’s approval is a sign that the FDA is confident in the safety and potential of the company’s technology.

Clinical trials are expected to begin in the coming months. The trial will be closely watched by the medical community and the public, as it will be the first time that Neuralink’s technology is tested in people.

The results of the trial will help to determine whether Neuralink’s technology is safe and effective and whether it has the potential to revolutionize the way people with neurological conditions live and interact with the world.

In addition to Neuralink, several other companies are developing brain-computer interfaces. BCIs are devices that can be used to record and stimulate neural activity.